Skip to content
10-Q/A

Quarterly Report

Eledon Pharmaceuticals, Inc. ELDN

0001193125-25-180904

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Aug 12, 2025 59.88M sh
Shares Diluted Q1 2025 · Mar 31, 2025 77.13M sh
Shares Diluted Q1 2025 · Mar 31, 2024 29.99M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$16.06M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$8.74M
Short Term Investments Q1 2025 · Mar 31, 2025 $116.39M
Short Term Investments Q1 2025 · Dec 31, 2024 $119.63M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $8.5M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $20.55M
Stockholders Equity restated Q1 2025 · Mar 31, 2025 $58.89M
Stockholders Equity restated Q1 2025 · Dec 31, 2024 $62.45M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 −$70.42M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 −$48.49M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.19M
Current Liabilities Q1 2025 · Dec 31, 2024 $11.58M
Total Liabilities Q1 2025 · Mar 31, 2025 $46.73M
Total Liabilities Q1 2025 · Dec 31, 2024 $59.27M
Current Assets Q1 2025 · Mar 31, 2025 $127.72M
Current Assets Q1 2025 · Dec 31, 2024 $143.73M
Total Assets Q1 2025 · Mar 31, 2025 $161.31M
Total Assets Q1 2025 · Dec 31, 2024 $177.41M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.08
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.65
Eps Basic Q1 2025 · Mar 31, 2025 −$0.08
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.65
Sga Expense Q1 2025 · Mar 31, 2025 $4.43M
Sga Expense Q1 2025 · Mar 31, 2024 $3.46M
Rd Expense Q1 2025 · Mar 31, 2025 $13.53M
Rd Expense Q1 2025 · Mar 31, 2024 $7.41M
Net Income Q1 2025 · Mar 31, 2025 −$6.5M
Net Income restated Q1 2025 · Mar 31, 2024 −$23.63M
Operating Income Q1 2025 · Mar 31, 2025 −$17.96M
Operating Income Q1 2025 · Mar 31, 2024 −$10.87M